Anti-CD39 and Anti-PD-1 Antibody Combination Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies targeting PD-1 often have limited efficacy and are not always complete or optimal, highlighting the need for additional therapeutic approaches that can enhance immunological responses against cancer.
Innovation Solution
Combination therapies involving antibodies specific to CD39 and PD-1 or PD-L1, which work together to modulate immune responses and increase the effectiveness of cancer treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-PD-1 or anti-PD-L1 antibodies are used as monotherapy, then immune response is activated, but efficacy is limited and not always complete or optimal
Solution Approach 1:
The patent combines anti-CD39 antibodies with anti-PD-1 or anti-PD-L1 antibodies to create a combination therapy. This merging of two different antibody mechanisms allows the therapeutic system to simultaneously block adenosine-mediated immunosuppression (via CD39) and activate T-cell responses (via PD-1/PD-L1), thereby achieving more complete and optimal efficacy than either agent alone.
2Object-generated harmful factors
If CD39 expression is increased in tumors, then ATP degradation to adenosine occurs, but this promotes anti-inflammatory state that suppresses anti-tumor immunity
Solution Approach 1:
The patent targets the harmful adenosine produced by CD39 enzyme activity and converts it into a beneficial therapeutic approach. By administering anti-CD39 antibodies, the therapy blocks the enzyme's ATP-degrading function, preventing harmful adenosine accumulation and its immunosuppressive effects, thereby transforming the tumor's adaptive mechanism into a treatable vulnerability.
3Object-affected harmful factors
If PD-1 pathway is activated by cancer cells, then T-cell activity is suppressed, but this prevents autoimmune diseases while also preventing cancer cell killing
Solution Approach 1:
The anti-PD-1 or anti-PD-L1 antibody acts as an intermediary that blocks the harmful PD-1 pathway interaction. By binding to PD-1 or PD-L1, the antibody prevents the suppressive signal from reaching T-cells, thereby removing the brake on anti-tumor immunity without causing autoimmune activation, as the blockage is specific to the cancer-driven PD-1 pathway.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of anti-CD39 and anti-PD-1 or anti-PD-L1 antibodies enhances T-cell proliferation, pro-inflammatory cytokine secretion, and anti-tumor responses, leading to improved clinical outcomes in cancer treatment.
Implementation Method 1
CD39 is an integral membrane protein that phosphohydrolyzes ATP to yield ADP and AMP. Given that CD39, along with other enzymes, degrades ATP, ADP, and AMP to adenosine, CD39 can be viewed as an immunological switch that shifts ATP-driven pro-inflammatory immune cell activity toward an anti-inflammatory state mediated by adenosine.
Implementation Method 2
PD-1 binds two ligands, PD-L1 and PD-L2. Both PD-1 ligands are members of the CD28-B7 family of co-signaling molecules that play important roles throughout all stages of T-cell function and other cell functions. The interaction of PD-1 and its ligands sends a signal into the T cell and essentially switches it off or inhibits it.
Data Source
AI summary
Provided herein are combination therapies involving antibodies with binding specificity for CD39 and antibodies with binding specificity for PD-1 and/or PD-L1.